Gabelli Weighs in on Endo International PLC’s FY2019 Earnings (ENDP)
Endo International PLC (NASDAQ:ENDP) – Investment analysts at Gabelli decreased their FY2019 EPS estimates for Endo International PLC in a report issued on Thursday. Gabelli analyst K. Kedra now anticipates that the brokerage will post earnings of $5.55 per share for the year, down from their previous forecast of $6.45. Gabelli also issued estimates for Endo International PLC’s FY2020 earnings at $6.30 EPS.
A number of other equities analysts have also weighed in on the company. JPMorgan Chase & Co. reissued an “overweight” rating and set a $40.00 price objective on shares of Endo International PLC in a research note on Tuesday, July 26th. Goldman Sachs Group Inc. started coverage on Endo International PLC in a research note on Monday, June 6th. They set a “neutral” rating and a $20.00 price objective on the stock. Zacks Investment Research raised Endo International PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, July 20th. Morgan Stanley set a $15.00 price objective on Endo International PLC and gave the stock a “hold” rating in a research note on Friday, August 5th. Finally, Vetr raised Endo International PLC from a “buy” rating to a “strong-buy” rating and set a $19.14 price objective on the stock in a research note on Monday, August 1st. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $37.50.
Shares of Endo International PLC (NASDAQ:ENDP) traded down 0.73% during midday trading on Monday, reaching $20.42. The company had a trading volume of 2,239,197 shares. The company’s 50 day moving average price is $21.29 and its 200-day moving average price is $20.88. Endo International PLC has a 52 week low of $12.56 and a 52 week high of $69.33. The company’s market capitalization is $4.55 billion.
Endo International PLC (NASDAQ:ENDP) last issued its quarterly earnings data on Monday, August 8th. The company reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.12. Endo International PLC had a positive return on equity of 15.54% and a negative net margin of 25.90%. The company had revenue of $921 million for the quarter, compared to the consensus estimate of $873.50 million. During the same quarter last year, the company earned $1.08 earnings per share. The firm’s revenue for the quarter was up 25.3% compared to the same quarter last year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Aperio Group LLC boosted its position in Endo International PLC by 1.7% in the first quarter. Aperio Group LLC now owns 43,200 shares of the company’s stock valued at $1,216,000 after buying an additional 732 shares in the last quarter. Massmutual Trust Co. FSB ADV boosted its position in Endo International PLC by 7.0% in the first quarter. Massmutual Trust Co. FSB ADV now owns 11,377 shares of the company’s stock valued at $320,000 after buying an additional 745 shares in the last quarter. Canada Pension Plan Investment Board boosted its position in Endo International PLC by 33.0% in the first quarter. Canada Pension Plan Investment Board now owns 9,019 shares of the company’s stock valued at $254,000 after buying an additional 2,237 shares in the last quarter. State Street Corp boosted its position in Endo International PLC by 1.0% in the first quarter. State Street Corp now owns 8,625,765 shares of the company’s stock valued at $242,813,000 after buying an additional 81,814 shares in the last quarter. Finally, Meeder Asset Management Inc. acquired a new position in Endo International PLC during the first quarter valued at about $139,000. 96.64% of the stock is owned by institutional investors and hedge funds.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.